Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate (2-HOF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00913263
Recruitment Status : Completed
First Posted : June 4, 2009
Results First Posted : January 19, 2015
Last Update Posted : January 19, 2015
Information provided by (Responsible Party):
Lidds AB

Brief Summary:
The primary objective was to evaluate efficacy of a single dose of Liproca Depot in patients with localized prostate cancer. Primary efficacy variable was the proportion of patients showing PSA nadir. 24 Caucasian men, with a mean age at inclusion of 68.4 years, with localized prostate cancer were injected once with a ready made paste including 600 mg 2-hydroxyflutamide (Liproca Depot) into the site of the prostate where the tumour was localized. The patient was monitored for prostate-specific antigen (PSA) for maximum 6 months or to progression within this time period. The primary endpoint showed interesting results with high success rate (83%), i.e. proportion of patients (Responders) that reached plasma PSA nadir.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: 2-hydroxyflutamide (2-HOF) [Liproca Depot] Drug: 2-Hydroxyflutamide Phase 1 Phase 2

Detailed Description:
Patients with localized prostate cancer were followed to progression or maximum 24 weeks after a single injection in one lobe of 2-8 mL ready-made paste (corresponding to 400-1600 mg 2-Hydroxyflutamid). Progression was defined as an increase in PSA by > 25% over baseline or on-treatment nadir.Among the 24 patients the primary endpoint, plasma PSA nadir, was reached by 20 patients (Responders). Efficacy was measured primarily as PSA nadir, and secondly as time to PSA nadir and prostate volume change. Safety was monitored throughout the whole study period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer
Study Start Date : June 2009
Actual Primary Completion Date : May 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: 2-Hydroxyflutamide
Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
Drug: 2-hydroxyflutamide (2-HOF) [Liproca Depot]
Ready made paste including 600 mg 2-HOF for injection as a single dose
Other Name: Liproca Depot

Drug: 2-Hydroxyflutamide
The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
Other Name: Liproca Depot

Primary Outcome Measures :
  1. Proportion of Patients Showing PSA Nadir [ Time Frame: Measured every 4th week until progression or maximum 6 months. ]
    Plasma PSA nadir is the lowest PSA reading achieved after any treatment for prostate cancer. The patients were observed once every 4th week during the study period.

Secondary Outcome Measures :
  1. Number of Patients Reporting Adverse Events Caused by the Study Treatment [ Time Frame: Measured every 4th week till progression or maximum 6 months ]
    • Adverse events caused by the study treatment
    • Abnormal, clinically relevant, laboratory parameters
    • Voiding symptoms
    • Vital Signs
    • Quality of Life

  2. Percent Change in Prostate Volume From Baseline to Nadir. [ Time Frame: Measured every 4th week until progression or maximum 6 months. ]
    Prostate volume was measured at each visit to capture nadir and compared to baseline for all patients. Decrease in prostate volume is reported as percent change from baseline.

  3. Time to PSA Nadir [ Time Frame: Measured every 4th week until progression or maximum 6 moths. ]
    Time frame was from baseline to day of PSA nadir.

  4. Percent Change in Prostate Volume From Baseline to Final Visit [ Time Frame: Measured every 4th week until progresion or maximum 6 months. ]
    Prostate volume was captured at each visit and percent change from baseline to final visit was measured. Final visit was either day of progression or after 6 months. Prostate volume decrease is reported in percent change from baseline

  5. Number of Days to Prostate Volume Nadir. [ Time Frame: Measured every 4th week until progression or maximum 6 months. ]
    Number of Days from day of injection to prostate volume nadir.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 45years
  2. Histologically confirmed localized prostate cancer (T1-T2), predominantly in one side of the peripheral zone, verified by biopsy.
  3. PSA value < 20 ng/ml within 6 weeks before enrolment.
  4. Gleason score ≤ 3+4 at diagnostic biopsy
  5. Adequate renal function: Creatinine < 1.5 times upper limit of normal.
  6. Adequate hepatic function: ASAT, ALAT and ALP < 1.5 times upper limit of normal.
  7. Negative dipstick for bacturia.
  8. Patient must have ability to cope with the study procedures and to return to scheduled visits including follow up visit.

Exclusion Criteria:

  1. Previous or ongoing hormone therapy for prostate cancer.
  2. Ongoing or previous therapy (within3 month) of finasteride or dutasteride.
  3. Ongoing or previous invasive therapy for benign prostate hyperplasia (TURP, TUMT).
  4. Symptoms or signs of acute prostatitis.
  5. Symptoms or signs of ulceric proctitis
  6. Severe micturation symptoms (I-PSS >17)
  7. Concomitant systemic treatment with corticosteroids, or immunomodulating agents.
  8. Known immunosuppressive disease (e.g. HIV, insulin dependent diabetes).
  9. Simultaneous participation in any other study involving not market authorized drugs or having participated in a study within the last 12 months prior to start of study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00913263

Layout table for location information
Tampere University Hospital
Tampere, Finland, 33520
Tampere University Hospital
Tampere, Finland
Sponsors and Collaborators
Lidds AB
Layout table for investigator information
Principal Investigator: Teuvo Tammela, Professor Tampere University Hospital
Layout table for additonal information
Responsible Party: Lidds AB Identifier: NCT00913263    
Other Study ID Numbers: LPC-002
2009-010079-25 ( EudraCT Number )
First Posted: June 4, 2009    Key Record Dates
Results First Posted: January 19, 2015
Last Update Posted: January 19, 2015
Last Verified: April 2013
Keywords provided by Lidds AB:
Prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents